We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current GNOM market cap is 92.26M. The company's latest EPS is USD -6.5818 and P/E is -1.56.
| Quarter End | |||||
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | |||||
| Operating Income | |||||
| Net Income |
| Year End 30 November 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 6k | 60k | 323k | 572k | 300k |
| Operating Income | 0 | 0 | 0 | 0 | 0 |
| Net Income | 1.82M | 17.21M | -34.81M | -79.05M | -58.84M |
| Quarter End | |||||
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | |||||
| Total Liabilities | |||||
| Total Equity |
| Year End 30 November 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 18.74M | 84.48M | 262.33M | 212.3M | 97.1M |
| Total Liabilities | 9k | 2.53M | 6.76M | 2.95M | 4.07M |
| Total Equity | 18.73M | 81.95M | 255.57M | 209.34M | 93.03M |
| Market Cap | 92.26M |
| Price to Earnings Ratio | -1.56 |
| Price to Sales Ratio | 305.95 |
| Price to Cash Ratio | 491.87 |
| Price to Book Ratio | 0.99 |
| Dividend Yield | - |
| Shares Outstanding | 8.94M |
| Average Volume (1 week) | 37.18k |
| Average Volume (1 Month) | 58.25k |
| 52 Week Change | -16.37% |
| 52 Week High | 13.33 |
| 52 Week Low | 8.63 |
| Spread (Intraday) | 2.43 (21.26%) |
| Company Name | Global X Genomics and Biotechnology |
| Address |
corporation trust center wilmington, delaware 19801 |
| Website | https:// |
| Industry | mgmt invt offices, open-end (6722) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
